Neue Suche | Kongressdetail
Druckansicht
 
 

3rd Annual RAS Targeted Drug Development Summit!

Evvnt Promotion / evvnt
-
21.09.2021 - 23.09.2021  Online
Time: 8:00 am - 5:15 pm
 
Kongressthemen
As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.
Kongressorganizer (PCO)
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/790905-3?pid=4832

Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics and more
 

Anfragen und Anmeldung:

https://go.evvnt.com/790905-0?pid=4832
Herr Customer Service
 
Kategorien
Allgemeinmedizin
Sprache
Englisch
Kongressgebühr
USD 2099.00 - USD 4198.00
Teilnehmer erwartet
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

European Public Health Association (EUPHA)newTreeHelix - Forschung & Beratung WienHilfswerk AustriaÄrzte der WeltCharité International AcademyÖsterreichische Akademie der ÄrzteAlumni Club Medizinische Universität Wien